GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (def ...

Core Insights - Adial Pharmaceuticals has filed a new patent application for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients, with expected protection extending to at least 2044 [1][2] - The company is advancing the AD04 program alongside a pharmacokinetics study, and the new patent application is a result of a thorough examination of data after hiring new patent counsel [2] - AD04 is a genetically targeted, serotonin-3 receptor antagonist that has shown promising results in reducing drinking in heavy drinking patients during the ONWARD™ pivotal Phase 3 clinical trial, with no significant safety or tolerability concerns [3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, with AD04 being its lead investigational new drug [3] - The company believes AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [3]

Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study.Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study. This comes after the success of its first cohort as a treatment for Alcohol Use Disorder (AUD).Adial Pharmaceuticals notes that this study started last month and is expected to reach completion during the fourth quarter of this year. The data from ...

GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in he ...

GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, "Low-dose ondansetron: A candidate prospective precision medicine to treat al ...

Core Insights - Adial Pharmaceuticals published results from its Phase 3 ONWARD study in the European Journal of Internal Medicine, demonstrating the efficacy of AD04 (low-dose ondansetron) in reducing heavy drinking days among patients with Alcohol Use Disorder (AUD) and specific genetic profiles [1][2] Group 1: Study Findings - AD04 significantly decreased the monthly percentage of heavy drinking days after 6 months of treatment among heavy drinking individuals with AUD and a specific genetic profile [2] - The genetic profile involved variants in the serotonin transporter and serotonin-AB receptor complex [2] - Adverse events (AEs) associated with AD04 were comparable to those of the placebo, indicating a favorable safety profile [2][3] - The combination of AD04 with psychosocial interventions may enhance treatment perceptions and increase demand among individuals who might not have sought treatment otherwise [2] Group 2: Implications for Precision Medicine - The findings highlight the potential of AD04 as a precision medicine, emphasizing the importance of genetic and behavioral factors in treating AUD [2] - The study suggests that patients with specific genetic backgrounds who are heavy drinkers experienced a reduction in heavy drinking days after treatment with AD04 [2] - The research indicates that no existing studies in alcohol literature have shown a medication with a similar AE profile to a placebo, underscoring the uniqueness of AD04's safety profile [2] Group 3: Company Overview - Adial Pharmaceuticals is focused on developing treatments for addictions and related disorders, with AD04 being a genetically targeted therapeutic agent for AUD [3] - The ONWARD trial showed promising results in reducing alcohol consumption in heavy drinkers without significant safety concerns [3] - AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [3]

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin withDecades of time and more modest sums of capitalMore modest sums of capital and a combination of risk and luckWe will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. Investing in sub-$2 stocks is very risky. Direct t ...

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the first patient has been dosed in a pharmacokineti ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. ...